Related Experiment Video

Updated: Jun 5, 2026

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
14:24

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

Published on: January 21, 2018

[Current perspectives in cell therapy in cardiology: an overview of ongoing trials]

Paolo Scacciatella1, Gianluca Amato, Elisa Ebrille

  • 1Struttura Complessa a Direzione Ospedaliera Cardiologia 2, Azienda Ospedaliera Universitaria San Giovanni Battista-Molinette, Torino. paolo.scacciatella@tin.it

Giornale Italiano Di Cardiologia (2006)
|January 21, 2011
PubMed
Abstract

Insights

Cardiac cell therapy trials are expanding globally, with most focusing on cell implantation for acute coronary syndrome and heart failure. This analysis aids future clinical trial planning in regenerative cardiology.

Area of Science:

  • Regenerative Medicine
  • Cardiovascular Research
  • Clinical Trial Analysis

Context:

  • Cardiac cell therapy remains largely experimental, necessitating a comprehensive understanding of ongoing clinical trials.
  • The landscape of cardiac cell therapy research is rapidly evolving, with numerous studies underway globally.
  • Effective planning of future clinical trials requires an in-depth analysis of current research trends and methodologies.

Purpose:

  • To provide an analytic overview of worldwide ongoing clinical trials in cardiac cell therapy.
  • To identify key trends in trial design, patient populations, and therapeutic strategies.
  • To offer insights for optimizing the planning and execution of future cardiac cell therapy clinical trials.

Summary:

  • A global analysis of 95 registered clinical trials (as of May 30, 2009) revealed a strong emphasis on cell implantation (92%) over cell mobilization (8%).
  • The majority of trials focused on acute coronary syndrome (46%) and heart failure (30%), primarily utilizing mononuclear cells (81%).
  • Europe led trial conduct (40 studies), with a significant proportion of studies in Phase 2 (57%) and employing randomized designs (78%).

Impact:

  • This comprehensive snapshot of the cardiac cell therapy trial landscape provides crucial data for researchers and clinicians.
  • Findings can inform the strategic development of new clinical programs, optimizing patient selection and therapeutic approaches.
  • The analysis highlights the need for continued research and development in cardiac regenerative medicine to address unmet clinical needs.

More Related Videos

Construction of Defined Human Engineered Cardiac Tissues to Study Mechanisms of Cardiac Cell Therapy11:51

Construction of Defined Human Engineered Cardiac Tissues to Study Mechanisms of Cardiac Cell Therapy

Published on: March 1, 2016

Isolation, Characterization, and Differentiation of Cardiac Stem Cells from the Adult Mouse Heart11:45

Isolation, Characterization, and Differentiation of Cardiac Stem Cells from the Adult Mouse Heart

Published on: January 7, 2019

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.